Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aude Bonehill

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Human Gene Therapy|November 12, 2009
Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cellsBrenda De Keersmaecker, Carlo Heirman, Sabine Allard, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formulaSandra Van Lint, Sofie Wilgenhof, Carlo Heirman, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2007
Current approaches in dendritic cell generation and future implications for cancer immunotherapySandra Tuyaerts, Joeri L Aerts, Jurgen Corthals, et al.
Human Gene Therapy|June 24, 2004
Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cellsKarine Breckpot, Jurgen Corthals, Carlo Heirman, et al.
European Journal of Immunology|February 16, 2007
CD83 expression on dendritic cells and T cells: correlation with effective immune responsesCindy Aerts-Toegaert, Carlo Heirman, Sandra Tuyaerts, et al.
Cancer Gene Therapy|August 29, 2003
Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cellsSandra Tuyaerts, Annelies Michiels, Jurgen Corthals, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2014
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesSofie Wilgenhof, Jurgen Corthals, An M T Van Nuffel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2004
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II moleculesAude Bonehill, Carlo Heirman, Sandra Tuyaerts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNAAude Bonehill, Sandra Tuyaerts, An M T Van Nuffel, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2011
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientAn M T Van Nuffel, Daphné Benteyn, Sofie Wilgenhof, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Human Gene Therapy|November 12, 2009
Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cellsBrenda De Keersmaecker, Carlo Heirman, Sabine Allard, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formulaSandra Van Lint, Sofie Wilgenhof, Carlo Heirman, et al.
Cancer Immunology, Immunotherapy : CII|May 16, 2007
Current approaches in dendritic cell generation and future implications for cancer immunotherapySandra Tuyaerts, Joeri L Aerts, Jurgen Corthals, et al.
Human Gene Therapy|June 24, 2004
Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cellsKarine Breckpot, Jurgen Corthals, Carlo Heirman, et al.
European Journal of Immunology|February 16, 2007
CD83 expression on dendritic cells and T cells: correlation with effective immune responsesCindy Aerts-Toegaert, Carlo Heirman, Sandra Tuyaerts, et al.
Cancer Gene Therapy|August 29, 2003
Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cellsSandra Tuyaerts, Annelies Michiels, Jurgen Corthals, et al.
Cancer Immunology, Immunotherapy : CII|December 31, 2014
Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesSofie Wilgenhof, Jurgen Corthals, An M T Van Nuffel, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 22, 2004
Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II moleculesAude Bonehill, Carlo Heirman, Sandra Tuyaerts, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNAAude Bonehill, Sandra Tuyaerts, An M T Van Nuffel, et al.
Cancer Immunology, Immunotherapy : CII|December 14, 2011
Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patientAn M T Van Nuffel, Daphné Benteyn, Sofie Wilgenhof, et al.
Pageof 4